<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="214108">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00298701</url>
  </required_header>
  <id_info>
    <org_study_id>GT-11</org_study_id>
    <nct_id>NCT00298701</nct_id>
  </id_info>
  <brief_title>Tolerability of Grazax-R in Children</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase I Trial Investigating the Safety of GRAZAX-R in Children Aged 5-12 Years With Grass Pollen Induced Rhinoconjunctivitis (With/Without Asthma)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ALK-Abelló A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ALK-Abelló A/S</source>
  <brief_summary>
    <textblock>
      This trial is performed to assess whether the Grazax-R treatment is safe to use in children
      aged 5-12 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date>April 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of safety by recording of adverse events</measure>
  </primary_outcome>
  <enrollment>50</enrollment>
  <condition>Allergy</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALK Grass tablet</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Grass pollen induced rhinoconjunctivitis

          -  Boys and girls, 5-12 years of age

          -  Positive skin prick test to grass pollen

        Exclusion Criteria:

          -  Previous treatment with immunotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Simonsen, MD</last_name>
    <role>Study Director</role>
    <affiliation>ALK-Abelló A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tangstedter Landstrasse 77</name>
      <address>
        <city>Hamburg</city>
        <zip>22415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2006</verification_date>
  <lastchanged_date>May 3, 2006</lastchanged_date>
  <firstreceived_date>March 1, 2006</firstreceived_date>
  <keyword>Allergy</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
